Top View
- Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course
- Inflammatory High-Risk Breast Cancer
- Seizures and Syncope in the Cancer Patient
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- Busulfan (Myleran®) (“Byoo SUL Fan”)
- Long-Term and Low-Dose of Busulfan Is a Safe and Effective Second-Line
- Clinical Implications for Cediranib in Advanced Cervical Cancer
- Emetogenic Potential of Antineoplastic Agents
- DRUG NAME: Busulfan
- Chemical Compatibility of Chemoclave™ and Chemolock™
- Pharmacogenetic Analysis of Liver Toxicity After Busulfan/Cyclophosphamide-Based Allogeneic Hematopoietic Stem Cell Transplantation
- A Phase IIA Study of the Addition of Temozolomide
- Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth Yulian P
- The Immunomodulatory Effects of Arsenic Trioxide in Autoimmunity and Alloreactivity Yishan Ye
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- Trisenox, INN-Arsenic Trioxide
- Emetogenic Potential of Antineoplastic Agents
- Pharmaceuticals Utilized in Stem Cell Transplant
- Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan
- Clinical Features and Treatment of Hematopoietic Stem Cell Transplantation- Associated Gastric Antral Vascular Ectasia
- Busulfan (Myleran®) (“Byoo-SUL-Fan”)
- Hydroxycarbamide for Acute Myeloid Leukaemia (AML)
- Drug-Induced Hyperpigmentation: Review and Case Series
- Prolonged Molecular Remission After Arsenic Trioxide and All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Relapsed After Allogeneic Stem Cell Transplantation
- Essential Thrombocythaemia (ET)
- A Randomized Trial to Compare Busulfan + Melphalan 140 Mg/M2
- High Dose Chemotherapy with Busulfan, Cyclophosphamide, and Etoposide As Conditioning Regimen for Allogeneic Bone Marrow Transpl
- List of Off‐Patent, Off‐Exclusivity Drugs Without an Approved Generic to Improve Transparency and Encourage T
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- CMS Manual System Human Services (DHHS) Pub
- Adverse Mucocutaneous Reactions Related to Chemothera- Peutic Agents – Part II Reações Tegumentares Adversas Relacionadas Aos Agentes Antineoplásicos – Parte II
- Intravenous Busulfan/Cyclophosphamide for Sibling Allograft
- Dose Modification Protocol Using Intravenous
- Consolidation with a Busulfan-Containing Regimen Followed by Stem Cell Transplantation in Infants with Poor Prognosis Stage 4 Neuroblastoma
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- SCIENCE CHINA a Drug from Poison: How the Therapeutic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Was Discovered
- Do Not Tube List
- November 22, 2020 Molnlycke Health Care, US LLC Leonard Stewart
- Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections Valerie W. C. Soo1£, Brian W. Kwan 1£, Héctor Queza
- Busulfan) for Injection Seizures: Initiate Anticonvulsant Prophylactic Therapy Prior to Initial U.S
- Arsenic (Trioxide)
- Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study
- Temozolomide Induces Senescence but Not Apoptosis in Human Melanoma Cells
- Hydroxyurea Inclusion.Pdf
- Hazardous Drug List
- Pan London Myeloproliferative Neoplasms (MPN) Guidelines
- Medications That Are Considered Hazardous
- High-Dose Busulfan, Melphalan, Thiotepa and Peripheral Blood Stem Cell Infusion for the Treatment of Metastatic Breast Cancer
- Arsenic Trioxide-Based Therapy of Relapsed Acute Promyelocytic Leukemia: Registry Results from the European Leukemianet
- Busulfan, Cyclophosphamide and Etoposide As High-Dose Conditioning Therapy in Patients with Malignant Lymphoma and Prior Dose-Limiting Radiation Therapy
- Antineoplastic Drugs